Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer

Eileen Parkes, Nuala McCabe, Richard Kennedy

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Recent trials of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, rucaparib and niraparib have resulted in approval of these agents in ovarian cancer, initially in patients with germline BRCA1 or BRCA2 mutations, now extended to the maintenance setting for all platinum-sensitive ovarian cancer. PARP inhibitors were first developed as chemo-sensitising agents and early clinical trials focused on combination treatment with DNA-damaging chemotherapy. However, the identification of synthetic lethality of PARP inhibitor treatment in BRCA1 and BRCA2-mutant cancer led to trials in BRCA1/2-mutant ovarian cancer with clinical responses to single agent treatment. These DNA-repair targeted agents have been a success story of translational research. However, questions remain over their optimal use in ovarian cancer and the effectiveness of currently available predictive biomarkers.
Original languageEnglish
Title of host publicationOncogenomics: From Basic Research to Precision Medicine
EditorsFranco Dammacco
PublisherAcademic Press
Chapter36
Pages521-528
Number of pages8
Edition1
ISBN (Print)012811789, 9780128117866
Publication statusPublished - 05 Nov 2018

Keywords

  • BRCA1
  • BRCA2
  • Ovarian cancer
  • Biomarker
  • DNA repair

Fingerprint Dive into the research topics of 'Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer'. Together they form a unique fingerprint.

Cite this